The U.S. Food and Drug Administration is putting new warning labels on popular weight loss and diabetes drugs, including Ozempic and Wegovy. The labels are due to a rare side effect that could lead to vision loss. The FDA has warned that people who take popular weight-loss drugs carry a small risk of developing a side effect that could lead to permanent vision loss.
What the FDA is requiring
The FDA has instructed all GLP-1 drugmakers to affix new warning labels to their products. In a drug safety communication, the agency said it will now require makers of GLP-1 receptor agonist drugs to add a warning about the NAION risk to their drug labels. The eye condition, non-arteritic anterior ischemic optic neuropathy, can cause significant vision loss.
Overlapping risk factors
Risk factors for the eye condition include diabetes, high blood pressure and sleep apnea, which are also common among patients prescribed GLP-1 drugs. The full list of NAION risk factors also includes cardiovascular disease, high cholesterol and metabolic syndrome, and their prevalence among GLP-1 users complicates assessment of a potential link. The FDA acknowledged that this overlap made it difficult to determine whether the medications themselves were responsible for the increased incidence of vision loss.